Abbott, a U.S. pharmaceutical company, will invest around 150 million dollars in the construction of a plant in Querétaro, Mexico.
This facility will be dedicated to the manufacturing of medical devices for the diagnosis and treatment of abnormal heart conditions, such as atrial fibrillation.
The plant, located north of the Santa Rosa Jáuregui delegation in the capital of the state of Querétaro, is expected to begin production of cardiovascular devices in a 20,000 square meter facility by mid-2025.
This will be Abbott's first plant in Mexico and will add to existing operations in the United States and Costa Rica.
From this new complex, the company will support its goal of making technology available worldwide. The investment in the plant was announced at a meeting with the governor of Querétaro, Mauricio Kuri González, who highlighted the importance of this investment for the region.
Initially, Abbott will employ 400 people in Querétaro, with plans to increase that number to more than 1,200 as operations expand. The company is recruiting personnel in areas such as engineering, quality control, manufacturing, and supply chain.
The location of Querétaro was chosen due to its proximity to educational institutions and talent development in various industries, such as automotive, aerospace, and electronics. Abbott provides information about job opportunities on its website.
Information from: El Economista.
Receive all industry news in our weekly Newsletter Dialéctica Científica.